about
The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemiaMinimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia.Evaluation of coagulopathy before and during induction chemotherapy for acute lymphoblastic leukaemia, including assessment of global clotting tests.Improved survival in matched unrelated donor transplant for childhood ALL since the introduction of high-resolution matching at HLA class I and II.Parthenolide eliminates leukemia-initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia.Expression of prolactin receptor mRNA in oestrogen receptor positive breast cancers pre- and post-tamoxifen therapy.The granulocytes in neutropenia 1 (GIN 1) study: a safety study of granulocytes collected from whole blood and stored in additive solution and plasma.Correlation between microsatellite discrepancy scores and transplant outcome after haemopoietic SCT for pediatric ALL.Inhibition affecting RQ-PCR-based assessment of minimal residual disease in acute lymphoblastic leukemia: reversal by addition of bovine serum albumin.Dismal long-term prognosis for children with refractory acute myeloid leukaemia treated with gemtuzumab ozogamicin and stem cell transplantation: where now?High peripheral blood progenitor cell counts enable autologous backup before stem cell transplantation for malignant infantile osteopetrosisPregnancy, tacrolimus, and renal transplantation: survival of a 358-g babySecond malignancies in children: the usual suspects?The impact of hyperglycemia on risk of infection and early death during induction therapy for acute lymphoblastic leukemia (ALL)Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGSStandardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study
P50
Q35094049-A421BE2B-53F4-42E5-A311-302ABE5AC0AFQ35161219-BED272D2-C3E9-40C1-82BA-6CAFB824B7D2Q41080113-163BF35D-18D6-4155-9E19-B0E80AFDB279Q43989922-DCED5C99-E214-4469-84E9-09772AD455B2Q44464540-F75C2012-1D7A-4F3A-9F48-8F98E44157FAQ44890342-A0420958-43B9-4CA4-858C-C12D696B4EE8Q47576193-95A571E8-DEF4-4FF2-9762-C3ABDFD25A63Q48236316-72CA7020-7269-4749-917E-48E71475CD74Q54795123-133BC17D-6153-4122-8667-12A231B68678Q61851816-898A1E6D-4D1F-4F68-9A53-C496A4929E1CQ61851820-0D41C22B-1E9E-490E-B618-9D67E099179FQ73235888-F2B13C70-AB74-4E7E-954B-F943CDEC9EFFQ73999884-BCD9AE6D-A7C6-4011-AF81-92660B430194Q87117903-A2691D7E-E8B2-4736-A880-47EF2261AF0DQ92948748-A590BCC2-0CCE-4B4D-898E-7E5748EC5969Q93053220-DAEE3C34-5682-4D87-8686-C9EE0BECEAF3
P50
description
researcher ORCID ID = 0000-0003-1844-3531
@en
name
J Moppett
@ast
J Moppett
@en
J Moppett
@nl
type
label
J Moppett
@ast
J Moppett
@en
J Moppett
@nl
prefLabel
J Moppett
@ast
J Moppett
@en
J Moppett
@nl
P31
P496
0000-0003-1844-3531